These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1205 related articles for article (PubMed ID: 28666462)
1. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462 [TBL] [Abstract][Full Text] [Related]
2. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158 [TBL] [Abstract][Full Text] [Related]
3. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. Morrison MM; Young CD; Wang S; Sobolik T; Sanchez VM; Hicks DJ; Cook RS; Brantley-Sieders DM PLoS Genet; 2015 Jul; 11(7):e1005291. PubMed ID: 26132202 [TBL] [Abstract][Full Text] [Related]
4. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655 [TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206 [TBL] [Abstract][Full Text] [Related]
8. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma. Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166 [TBL] [Abstract][Full Text] [Related]
9. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172 [TBL] [Abstract][Full Text] [Related]
10. MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Xu K; Chen G; Li X; Wu X; Chang Z; Xu J; Zhu Y; Yin P; Liang X; Dong L Sci Rep; 2017 Feb; 7():41718. PubMed ID: 28176801 [TBL] [Abstract][Full Text] [Related]
11. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045 [TBL] [Abstract][Full Text] [Related]
12. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. Kim EK; Yun SJ; Ha JM; Kim YW; Jin IH; Yun J; Shin HK; Song SH; Kim JH; Lee JS; Kim CD; Bae SS Oncogene; 2011 Jun; 30(26):2954-63. PubMed ID: 21339740 [TBL] [Abstract][Full Text] [Related]
13. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318 [TBL] [Abstract][Full Text] [Related]
14. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. Zhao Y; Wang Z; Jiang Y; Yang C Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825 [TBL] [Abstract][Full Text] [Related]
15. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Gulhati P; Bowen KA; Liu J; Stevens PD; Rychahou PG; Chen M; Lee EY; Weiss HL; O'Connor KL; Gao T; Evers BM Cancer Res; 2011 May; 71(9):3246-56. PubMed ID: 21430067 [TBL] [Abstract][Full Text] [Related]
16. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition. Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061 [TBL] [Abstract][Full Text] [Related]
17. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers. Beck C; Rodriguez-Vargas JM; Boehler C; Robert I; Heyer V; Hanini N; Gauthier LR; Tissier A; Schreiber V; Elofsson M; Reina San Martin B; Dantzer F Cell Death Differ; 2019 Sep; 26(9):1615-1630. PubMed ID: 30442946 [TBL] [Abstract][Full Text] [Related]
18. mTORC2 Suppresses GSK3-Dependent Snail Degradation to Positively Regulate Cancer Cell Invasion and Metastasis. Zhang S; Qian G; Zhang QQ; Yao Y; Wang D; Chen ZG; Wang LJ; Chen M; Sun SY Cancer Res; 2019 Jul; 79(14):3725-3736. PubMed ID: 31142514 [TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802 [TBL] [Abstract][Full Text] [Related]
20. The guanine nucleotide exchange factor Tiam1: a Janus-faced molecule in cellular signaling. Boissier P; Huynh-Do U Cell Signal; 2014 Mar; 26(3):483-91. PubMed ID: 24308970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]